Journal
JOURNAL OF CYSTIC FIBROSIS
Volume 14, Issue 3, Pages 412-413Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcf.2014.07.013
Keywords
Rhinosinusitis; Ivacaftor; CFTR potentiator; Cystic Fibrosis; Computed Tomography
Categories
Ask authors/readers for more resources
In patients with Cystic Fibrosis and a type III mutation, ivacaftor (Kalydeco (R), Vertex) can increase the opening time of the CFTR channel and improve chloride transport. Research showed significant improvement of lung function and increase in weight following ivacaftor use. However, ivacaftor showed to have adverse events on the sinonasal system as well, such as upper respiratory tract infections, nasal congestion and headaches. This case report showed a positive effect of ivacaftor on the sinonasal pathology in a 17 year old patient with CF. After 5 months of ivacaftor use, the CT-sinus showed complete resolution of the pacification of the paranasal sinuses and a decrease in symptoms of sinonasal disease. This positive effect of ivacaftor on sinonasal pathology seems promising, therefore more research is needed to evaluate the effect of ivacaftor on the upper airways in CF. (C) 2014 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available